PD-L1 Expression in Relation to Patients With Thyroid Cancer
Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.
Christine Dierks, MD, senior physician at the University Hospital Freilburg in Germany, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.
Dierks says that regarding the PD-L1 levels used for the tumor proportion score (TPS) and combined positive score (CPS), physicians look at the PD-L1 expression on the membrane of the tumor cells. They also look at the frequency of the infiltrating immune cells and infiltrating lymphocytes to see if they express PD-L1 or PD-1 on the cell’s surface. To histologically characterize the immune phenotype of a tumor, they need to see the level of expression on these different parts of the tumor.
With differentiated thyroid carcinoma, physicians usually see TPS that is either negative or very low, below 10%. In over 70% of patients with anaplastic thyroid carcinoma, the TPS is often above 50% and the CPS above 75%, according to Dierks. She says these scores are some of the prognostic markers for response to immune checkpoint inhibitors in patients with non–small cell lung cancer.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
